Noriko Satake, M.D.

Associate Professor

To see if Noriko Satake is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Reviews

Specialties

Pediatrics

Pediatric Hematology/Oncology

Hematology/Oncology

Department

Pediatrics

Locations and Contact

2279 45th Street
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Phone

916-703-2601

Clinic Fax

916-451-3014

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Satake is a board certified pediatric hematologist and oncologist offering care for children with various cancers. She is also interested in developing new treatments and cell therapies.

Research/Academic Interests

Dr. Satake's research focuses on understanding molecular mechanisms in childhood cancers (and cancer stem cells) and identifying novel targets. Her ultimate goal is to develop more effective treatments with fewer side effects than current therapies for children with cancers. She has established a tissue repository and developed a series of patient-derived leukemia xenograft mouse models, which serve as precious tools to conduct her research.

Division

Pediatric Hematology/Oncology

Center/Program Affiliation

Stem Cell Research Program
Stem Cell Transplant Program
UC Davis Children's Hospital
UC Davis Comprehensive Cancer Center

Medical School

M.D., Asahikawa Medical College, Asahikawa, Japan 1990

Residency

Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan 1990-1994

Residency

Pediatrics, Wright State University, Dayton OH 2001-2003

Fellowship

Hematology/Oncology, Saitama Cancer Center Hospital, Saitama, Japan 1994-1996

Fellowship

Pediatric Hematology/Oncology, UCLA, Los Angeles CA 2003-2006

Distinguished Alumni Award (Asahikawa Medical School, Japan), 2016

Yoshida S, Duong C, Oestergaard M, Fazio M, Chen C, Peralta R, Guo S, Seth PP, Li Y, Beckett L, Nitin N, Satake N. MXD3 Antisense Oligonucleotide With Superparamagnetic Iron Oxide Nanoparticles: A New Targeted Approach for Neuroblastoma. Nanomedicine. 2020 Feb;24:102127. doi:10.1016/j.nano.2019.102127. Epub 2019 Nov 26.

Yoshida S, Tuscano E, Duong C, Chung J, Li Y, Beckett L, Tuscano JM, Satake N. Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B cell Acute Lymphoblastic Leukemia. Leuk Lymphoma. 2017 May;58(5):1254-1257. doi:10.1080/10428194.2016.1235273. Epub 2016 Oct 5.

Doung C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N. Novel Targeted Therapy for Neuroblastoma: Silencing the MXD3 Gene Using siRNA. Pediatr Res. 2017 Sep;82(3):527-535. doi:10.1038/pr.2017.74. Epub 2017 May 31.

Satake N, Duong C, Yoshida S, Oestergaard M, Chen C, Peralta R, Guo S, Seth PP, Li Y, Beckett L, Chung J, Nolta J, Nitin N, Tuscano JM. Novel Targeted Therapy for Precursor B Cell ALL: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. Mol Med. 2016 Oct;22:632-642. doi:10.2119/molmed.2015.00210. Epub 2016 Jul 22.

Barisone GA, Satake N, Lewis C, Duong C, Chen C, Lam K, Nolta J, Diaz E. Loss of MXD3 Induces Apoptosis of Human Precursor B cell Acute Lymphoblastic Leukemia cells. Blood Cells Mol Dis. 2015 Apr;54(4):329-335. Published online 2014 Dec 20. doi:10.1016/j.bcmd.2014.12.002.

Satake N, Duong C, Chen C, Barisone GA, Diaz E, Tuscano J, Rocke DM, Nolta J, Nitin N. Targeted Therapy with MXD3 siRNA, antiCD22 Antibody, and Nanoparticles for Precursor B-Cell Acute Lymphoblastic Leujemia. Br J Haematol. 2014 Nov;167(4):487-499. doi:10.1111/bjh.13066. Epub 2014 Sep 8.

Satake N, Duong C, Yoshida S, Davis R, Liu S, Van Dyke J, McLaughlin B, Nolta J, Nitin N, Tepper C. Leukemia Stem Cells in Acute Lymphoblastic Leukemia: Unveiling Hierarchical Structure at Single Cell Resolution. Blood. 2014 Dec 6;124(21):4786. doi:10.1182/blood.V124.21.4786.4786.

Yoshida S, Tuscano ET, Duong C, Tuscano JM, Satake N. Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B cell Acute Lymphoblastic Leukemia. Blood. 2014;124(21):971. doi:10.1182/blood.V124.21.971.971.

Duong C, Oestergaard M, Yoshida S, Chen C, Nolta J, Guo S, Seth P, Nithin N, Tuscano JM, Satake N. Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugates. Blood. 2014;124(21):3719. doi:10.1182/blood.V124.21.3719.3719.

Duong C, Chen C, Yoshida S, Barisone G, Nolta J, Dia E, Nitin N, Satake N. Abstract 5423: Novel Targeted Therapy for Neuroblastoma: Silencing the MXD3 Gene Using siRNA. Cancer Res. 2014;74(19 Suppl):Abstract nr 5423. doi:10.1158/1538-7445.AM2014-5423 Published October 2014.